financetom
Business
financetom
/
Business
/
Toyota backs Japanese space startup Interstellar to mass-produce rockets
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Toyota backs Japanese space startup Interstellar to mass-produce rockets
Jan 6, 2025 5:08 PM

Jan 7 (Reuters) -

A Toyota ( TM ) research unit will invest in Japanese

startup Interstellar Technologies (IST) to support mass

production of its rockets, the world's biggest carmaker group

said on Tuesday, expanding its foray into the space sector.

IST said that Woven by Toyota ( TM ), a Toyota ( TM ) subsidiary that

is building a "

city of the future

" in Japan with autonomous driving technology, will invest

about 7 billion yen ($44.4 million) in IST by the first close of

its Series F funding.

As part of the capital and business tie-up, Woven will

appoint a director to IST's board and support rocket production

by strengthening supply chains and corporate governance, IST

said in a

statement.

The announcement came after Toyota ( TM ) Chairman Akio

Toyoda's

speech

at the CES trade show in Las Vegas on Monday, where he gave

updates to the company's experimental Woven City project, which

was announced in 2020.

"The future of mobility shouldn't be limited to just

Earth, or just one car company," Toyoda said. "Speaking of the

sky, we're exploring rockets, too."

Apart from launchers, Toyota ( TM ) is building a

lunar rover

with Japan's space agency that can carry astronauts on the

moon's surface for the NASA-led Artemis programme.

The commercial race for space has accelerated over the

past decade, led by Elon Musk's rocket and satellite company

SpaceX.

The Hokkaido-based IST in 2019 became the first Japanese

company to send a commercially developed rocket into space, but

its orbital launcher, Zero, remains under development.

IST's rival Space One last month attempted a second flight

of its orbital rocket Kairos, but the launch failed.

The Japanese government

aims

to launch 30 rockets annually by the early 2030s and make

Japan Asia's space hub, with an 8 trillion yen space industry,

granting subsidies to startups such as IST and Space One.

($1 = 157.6000 yen)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Roblox Insider Sold Shares Worth $27,698,899, According to a Recent SEC Filing
Roblox Insider Sold Shares Worth $27,698,899, According to a Recent SEC Filing
Dec 9, 2024
05:44 PM EST, 12/09/2024 (MT Newswires) -- David Baszucki, 10% Owner, Director, President & CEO, on December 05, 2024, sold 483,335 shares in Roblox ( RBLX ) for $27,698,899. Following the Form 4 filing with the SEC, Baszucki has control over a total of 1,004,280 shares of the company, with 129,295 shares held directly and 874,985 controlled indirectly. SEC Filing:...
Invesco Reports 4.8% Gain in November AUM
Invesco Reports 4.8% Gain in November AUM
Dec 9, 2024
05:43 PM EST, 12/09/2024 (MT Newswires) -- Invesco ( IVZ ) reported preliminary assets under management late Monday of $1.857 trillion at the end of November, up 4.8% month over month. The company said favorable market returns positively affected AUM by $52 billion and foreign exchange decreased it by $3 billion, respectively. ...
Nanobiotix's NBTXR3 Phase 1 Study Yields Promising Results for Pancreatic Cancer Treatment
Nanobiotix's NBTXR3 Phase 1 Study Yields Promising Results for Pancreatic Cancer Treatment
Dec 9, 2024
05:44 PM EST, 12/09/2024 (MT Newswires) -- Nanobiotix ( NBTX ) said late Monday it completed the dose escalation and expansion phases of a phase 1 study evaluating radiotherapy-activated NBTXR3 for patients with advanced or borderline resectable pancreatic cancer. The study showed promising results, with a 23-month median overall survival from diagnosis in 22 patients, compared to a 19.2-month historical...
Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours
Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours
Dec 9, 2024
05:43 PM EST, 12/09/2024 (MT Newswires) -- Biomea Fusion ( BMEA ) said late Monday that preliminary data from an ongoing phase I study of BMF-500 supports its potential as a transformative therapy for patients with FMS-like tyrosine kinase 3 mutated relapsed or refractory acute leukemia, a type of cancer. The investigational therapy demonstrated a favorable safety and tolerability profile...
Copyright 2023-2026 - www.financetom.com All Rights Reserved